
News|Articles|December 1, 2012
Aubagio (Teriflunomide)
New molecular entity: FDA approved teriflunomide (Aubagio, Genzyme, a Sanofi-Aventis company), a pyrimidine synthesis inhibitor, for the treatment of patients with relapsing forms of multiple sclerosis (MS).
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Researchers discover new pathway to fight liver inflammation
2
Overlooked bladder nerves now thought to reduce UTI burden through pain signaling, study shows
3
FDA approves $2.7 million gene therapy for rare metabolic disorder
4
FDA approves Pasatru, the second treatment for rare bone disorder
5





















